Journal
PEDIATRIC PULMONOLOGY
Volume 55, Issue 9, Pages 2272-2282Publisher
WILEY
DOI: 10.1002/ppul.24880
Keywords
inflammation; meconium aspiration syndrome; neonate; phosphodiesterase inhibitor; piglet; surfactant lavage
Categories
Funding
- Taipei Veterans General Hospital, Taipei, Taiwan [V 108C-159]
- Ministry of Science and Technology, Taipei, Taiwan [MOST 104-2314-B-010, MOST 104-2314-B-011, MOST 104-2314-B-012, MOST 104-2314-B-013, MOST 104-2314-B-014, MOST 104-2314-B-015, MOST 104-2314-B-016, MOST 104-2314-B-017, MOST 104-2314-B-018, MOST 104-2314-B-019, MOST 104-2314-B-020]
- [MOST 104-2314-B-021]
- [MOST 104-2314-B-022]
- [MOST 104-2314-B-023]
- [MOST 104-2314-B-024]
- [MOST 104-2314-B-025]
- [MOST 104-2314-B-026]
- [MOST 104-2314-B-027]
- [MOST 104-2314-B-028]
- [MOST 104-2314-B-029]
- [MOST 104-2314-B-030]
- [MOST 104-2314-B-031]
- [MOST 104-2314-B-032]
- [MOST 104-2314-B-033]
- [MOST 104-2314-B-034]
- [MOST 104-2314-B-035]
- [MOST 104-2314-B-036]
- [MOST 104-2314-B-037]
- [MOST 104-2314-B-038]
- [MOST 104-2314-B-039]
- [MOST 104-2314-B-040]
- [MOST 104-2314-B-041]
- [MOST 104-2314-B-042]
- [MOST 104-2314-B-043]
- [MOST 104-2314-B-044]
- [MOST 104-2314-B-045]
- [MOST 104-2314-B-046]
- [MOST 104-2314-B-047]
- [MOST 104-2314-B-048]
- [MOST 104-2314-B-049]
- [MOST 104-2314-B-050]
- [MOST 104-2314-B-051]
- [MOST 104-2314-B-052]
- [MOST 104-2314-B-053]
- [MOST 104-2314-B-054]
- [MOST 104-2314-B-055]
- [MOST 104-2314-B-056]
- [MOST 104-2314-B-057]
- [MOST 104-2314-B-058]
- [MOST 104-2314-B-059]
- [MOST 104-2314-B-060]
- [MOST 104-2314-B-061]
- [MOST 104-2314-B-062]
- [MOST 105-2314-B-010]
- [MOST 105-2314-B-011]
- [MOST 105-2314-B-012]
- [MOST 105-2314-B-013]
- [MOST 105-2314-B-014]
- [MOST 105-2314-B-015]
- [MOST 105-2314-B-021]
- [MOST 105-2314-B-022]
- [MOST 105-2314-B-023]
- [MOST 105-2314-B-024]
- [MOST 105-2314-B-025]
- [MOST 105-2314-B-026]
- [MOST 105-2314-B-027]
- [MOST 105-2314-B-028]
- [MOST 105-2314-B-029]
- [MOST 105-2314-B-030]
- [MOST 105-2314-B-031]
- [MOST 105-2314-B-032]
- [MOST 105-2314-B-033]
- [MOST 105-2314-B-034]
- [MOST 105-2314-B-035]
- [MOST 105-2314-B-036]
- [MOST 105-2314-B-037]
- [MOST 105-2314-B-038]
- [MOST 105-2314-B-039]
- [MOST 105-2314-B-040]
- [MOST 105-2314-B-041]
- [MOST 105-2314-B-042]
- [MOST 105-2314-B-043]
- [MOST 105-2314-B-044]
- [MOST 105-2314-B-016]
- [MOST 105-2314-B-017]
- [MOST 105-2314-B-018]
- [MOST 105-2314-B-019]
- [MOST 105-2314-B-020]
Ask authors/readers for more resources
Background Nonsteroidal anti-inflammatory drugs, such as selective phosphodiesterase type 4 (PDE4) inhibitors have potential anti-inflammatory and respiratory smooth muscle relaxation effects. This study aimed to investigate the pathophysiological effects of an intravenous PDE4 inhibitor (rolipram) and surfactant lavage (SL) in a newborn piglet model of meconium aspiration syndrome (MAS). Methods MAS was induced in 25 newborn piglets, which were randomly divided into control and four SL treatment groups administered with different doses of intravenous rolipram (0, 0.1, 0.5, and 1 mg/kg). Cardiopulmonary variables were monitored and recorded. The experimental time was 4 hours. Serial blood was drawn for blood gas and biomarker analyses. Lung tissue was examined for histological analysis. Results All SL-treated groups revealed improved oxygenation during the 4-hour experiments and had significantly lower peak inspiratory pressure levels than the control group at the end of experiments. All SL plus rolipram-treated groups exhibited significantly higher lung compliance than the control group. However, the animals receiving high-dose (0.5 and 1.0 mg/kg) rolipram demonstrated significantly elevated heart rates. Lung histology of the nondependent sites revealed significantly lower lung injury scores in all SL-treated groups compared with that in the control group, but there were no differences among the rolipram-treated groups. Conclusions In addition to SL, intravenous PDE4 inhibitors may further improve lung compliance in treating MAS; however, it is necessary to consider cardiovascular adverse effects, primarily tachycardia. Further investigations are required before the clinical application of intravenous PDE4 inhibitor as an anti-inflammatory agent to treat severe MAS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available